DB06475InvestigationalProtein Based Therapies
Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.
- Mechanism
- Curator reviewed
Ruplizumab is an anti-CD40L monoclonal antibody. The binding of CD40 to its ligand, CD40L, is a critical element in T cell activation. In systemic lupus erythematosus, CD40L is over-expressed on T cells, B cells, and monocytes.
- Primary indication
- Investigated for use/treatment in thrombocytopenia, systemic lupus erythematosus, transplant (rejection), blood (blood forming organ disorders, unspecified), and multiple sclerosis.Curator reviewed
- Also known as
- Recombinant humanized monoclonal antibody 5c8
- Code names
- BG-9588 · HU-5C8
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Ruplizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account